Rivaroxaban and Chronic Kidney Disease: evidence from the present and future prospects

Authors

  • Luca Di Lullo UOC Nefrologia e Dialisi, Ospedale L. Parodi – Delfino, Colleferro, Italy
  • Claudio Ronco International Renal Research Institute, Ospedale S. Bortolo, Vicenza, Italy
  • Fulvio Floccari UOC Nefrologia e Dialisi, Ospedale “S. Paolo”, Civitavecchia, Italy
  • Antonio De Pascalis UOC Nefrologia e Dialisi, Ospedale “V. Fazzi”, Lecce, Italy
  • Vincenzo Barbera UOC Nefrologia e Dialisi, Ospedale L. Parodi – Delfino, Colleferro, Italy
  • Rodolfo Rivera Clinica Nefrologica, Ospedale “S.Gerardo”, Monza, Italy
  • Antonio Bellasi Department of Research, Innovation and Brand Reputation, ASST (Azienda Socio Sanitaria Territoriale) Papa Giovanni XXIII, Bergamo, Italy

DOI:

https://doi.org/10.33393/gcnd.2019.507

Keywords:

Atrial fibrillation, Chronic kidney disease, Warfarin, Direct oral anticoagulants, Rivaroxaban

Abstract

Cardiovascular diseases represent the main cause of comorbidly in chronic kidney disease (CKD) patients, with a 7% incidence in atrial fibrillation (AF) in end-stage renal disease (ESRD) patients. Until recently, prophylactic treatment of atrial fibrillation complications (such as thromboembolism) was mainly based on vitamin K antagonists (VKA) or heparin. In the last years, direct oral anticoagulants (DOACs) have been made available; however, their renal clearance limits their use on patients with severe renal impairment (eGFR <15 mL/min). Among DOACs, Rivaroxaban, a factor X-activated (Xa) inhibitor, shows good renal profile and it can be used in CKD patients up to stage 4 as well as in ESRD patients (at the moment only in North America and Canada). (Cardionephrology)

Downloads

Download data is not yet available.

Published

2019-03-22

How to Cite

Di Lullo, L., Ronco, C., Floccari, F., De Pascalis, A., Barbera, V., Rivera, R., & Bellasi, A. (2019). Rivaroxaban and Chronic Kidney Disease: evidence from the present and future prospects. Giornale Di Clinica Nefrologica E Dialisi, 31(1), 30–36. https://doi.org/10.33393/gcnd.2019.507

Issue

Section

Cardionephrology

Metrics

Most read articles by the same author(s)

1 2 3 4 > >>